Comparative Pharmacology
Head-to-head clinical analysis: EPINEPHRINE AUTOINJECTOR versus LABETALOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINEPHRINE AUTOINJECTOR versus LABETALOL.
EPINEPHRINE (AUTOINJECTOR) vs Labetalol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acts directly on both alpha- and beta-adrenergic receptors. Alpha effects include vasoconstriction, increased peripheral resistance, and decreased mucosal edema. Beta effects include bronchodilation, positive chronotropic and inotropic cardiac activity, and increased systolic blood pressure.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
0.3 mg intramuscularly (IM) into the anterolateral thigh, repeated every 5–15 minutes as needed for anaphylaxis. Maximum dose: 0.3 mg per injection.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
None Documented
None Documented
2-3 minutes (phase I rapid redistribution); terminal half-life ~10 minutes
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Primarily renal (inactive metabolites); 90% renal, 10% biliary/fecal
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker